【Can-Fite BioPharma-Product CF101】Can-Fite BioPharma Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately

Partner News

13 April, 2020– Can-Fite BioPharma Ltd. issued an announcement, which is summarized as follows:

 Study will treat 40 COVID-19 infected patients hospitalized with moderate-to-severe symptoms

 Efficacy endpoints include viral shedding and resolution of symptoms

Can-Fite today announced it has received approval from the Institutional Review Board (IRB) at Rabin Medical Center to initiate a pilot clinical study of its drug candidate Piclidenoson for the treatment of moderate-to-severe symptoms in coronavirus (COVID-19) infected patients.

On March 23, 2020, Can-Fite announced it submitted Piclidenoson for a COVID-19 compassionate use program to the IRB at Rabin Medical Center. Upon review, the IRB recommended that Can-Fite advance into a full clinical study. Can-Fite submitted the study protocol, which has been approved by the IRB. Patient enrollment and dosing will begin immediately.

The original website link: